Reiko Kuni-Kamochi

Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies

S. Iida, Ryosuke Nakano, Naoko Yamane-Ohnuki, 2007, Cytotechnology.

Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.

Akira Okazaki, Shigeru Iida, Mitsuo Satoh, 2007, Journal of biotechnology.

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.

Akira Okazaki, Mitsuo Satoh, M. Inoue, 2007, Glycobiology.

Generation of an industrially ideal host cell line for producing completely-defucosylated antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC)

S. Iida, Ryosuke Nakano, Naoko Yamane-Ohnuki, 2006 .

Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA.

Kazuya Yamano, Shigeru Iida, Mitsuo Satoh, 2004, Biotechnology and bioengineering.

Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates.

Kazuo Suzuki, Y. Kanda, Reiko Kuni-Kamochi, 2014, Antiviral research.

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

S. Iida, H. Misaka, M. Inoue, 2009, BMC Cancer.